404 - Oops, something went wrong. The page you were trying to access or the link you clicked could not be accessed. But no problem! To quickly and conveniently find or retrieve content, you can use our newly developed Visual Sitemap. A search function exists. You can also browse the catalog block by block or page by page. It's worth it!
As a small compensation for not immediately showing you the content you were looking for, we take the liberty of offering you a voucher to extensively test all premium features for 30 days. Just click the button on the right side, log in to your account and activate the voucher code there.
.
Innate Pharma
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG000Q71CK5
IPH
Innate Pharma
GICS: 35201010
·
Sector: EQTY
·
Sub-Sector: -
NAME
Innate Pharma
ISIN
FR0010331421
TICKER
IPH
MIC
XPAR
REUTERS
IPH.PA
BLOOMBERG
IPH FP
F&G:
65
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Tue, 29.07.2025
Innate Pharma
FR0010331421
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the company’s CEO Jonathan Dickinson and COO Yannis Morel will participate in the BTIG Virtual Biotechnology Conference being held on July 29-30, 2025.
BTIG, a global financial services firm specializing in investment banking,...
Innate Pharma
Fri, 04.07.2025
Innate Pharma
FR0010331421
Regulatory News:
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as wel...
Innate Pharma
Tue, 17.06.2025
Innate Pharma
FR0010331421
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team will participate in the upcoming investor conferences, detailed below.
H.C. Wainwright 3rd Annual Immune Cell Engager Virtual Conference
Dates: June 24, 2025 | Virtual
Wolfe Research Virtual ...
Innate Pharma
Fri, 13.06.2025
Innate Pharma
FR0010331421
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of preclinical data for IPH6501, its proprietary ANKET® targeting CD20 currently under investigation in a Phase 1/2 study in relapsed and/or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) (NCT06088654), at the ...
Innate Pharma
Tue, 27.05.2025
Innate Pharma
FR0010331421
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team will present and host 1x1 meetings at the upcoming investor conferences, detailed below.
Jefferies Global Healthcare Conference
Dates: June 3 – 5 2025 | New York, USA
The executive team will part...
Innate Pharma
Fri, 23.05.2025
Innate Pharma
FR0010331421
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of long-term follow-up data from the Phase 2 TELLOMAK clinical trial evaluating lacutamab, an anti-KIR3DL2 monoclonal antibody, in patients with Sézary syndrome (SS) and mycosis fungoides (MF), two rare and aggressive...
Innate Pharma
Fri, 23.05.2025
Innate Pharma
FR0010331421
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 22, 2025, in Marseille. All resolutions were voted.
A total of 114 votes were cast out of a total of 43,447,237 shares giving right to 43...
Innate Pharma
Mon, 19.05.2025
Innate Pharma
FR0010331421
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate’s drugs in clinical development have been accepted for the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, taking place May 30-June 3, 2025 in Chicago, Illinois.
“We are looking forwa...
Innate Pharma
Thu, 15.05.2025
Innate Pharma
FR0010331421
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH6501, its ANKET® targeting CD20 B cells currently developed in relapsed and/or refractory Non-Hodgkin Lymphoma, has been selected for the European Hematology Association (EHA) Congress 2025, taking place ...
Innate Pharma
Tue, 13.05.2025
Innate Pharma
FR0010331421
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the quarter ending March 31, 2025.
“The first quarter of 2025 was marked by significant progress across both our pipeline and strategic partnerships,” said Jonathan Dickinson, Chief Executive Off...
Innate Pharma
Information on product placements
BARRISTA SMART * AD
P R O D U C T S U G G E S T I O N S
